Happy 4th of July! We hope everyone has a fun and safe holiday celebrating America’s independence with friends and family.
Atavistik Bio
Biotechnology Research
Cambridge, MA 1,693 followers
Precision allosteric therapeutics inspired by the body’s natural regulators
About us
Atavistik Bio is focused on unlocking hidden functional pockets to discover transformative allosteric precision therapeutics to address serious unmet patient needs. By integrating our propriety screening technology using the body’s natural regulators, with our powerful AI-enabled drug discovery platform, we are able to efficiently identify novel, biologically relevant allosteric sites for protein or RNA targets, and rapidly advance structural insights into small molecule therapeutics design. Atavistik is advancing multiple high value oncology programs and anticipates initiating clinical development in early 2025. Atavistik is based in Cambridge, MA and backed by leading biotech venture capital firms The Column Group, Nextech, and Lux Capital.
- Website
-
https://atavistikbio.com/
External link for Atavistik Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
- Founded
- 2021
Locations
-
Primary
Get directions
Cambridge, MA 02139, US
Employees at Atavistik Bio
Updates
-
Happy one-year anniversary, Rajiv Gandhi Govindaraj! Thank you for implementing state-of-the-art, allostery-focused computational methods to advance our projects. Your innovative approaches combined with a can-do attitude have had a tremendous impact in tackling ambitious goals during your first year. Cheers to many more successful years ahead!
-
-
As #Pride Month draws to a close on International Pride Day, we celebrate and honor the progress that the LGBTQ+ community has made and continues to make. This month, our team gathered to explore the vibrant history of the LGBTQ+ community and the evolution of the iconic #Pride flag. Celebrate with us as we honor the beauty of diversity! Happy Pride!
-
-
We are thrilled to announce that Maria-Jesus Blanco, SVP, Head of Drug Discovery, will be presenting a talk at this year’s National Medicinal Chemistry Symposium in Seattle, WA. We also extend our warmest congratulations to her for being named the 2024 recipient of The Division of Medicinal Chemistry Award! She will receive this prestigious award during the MEDI award session. More info here: https://www.nmcsmedi.org/
-
-
At Atavistik Bio, we are dedicated to discovering the next generation of precision allosteric therapeutics while fostering a diverse and inclusive workplace. We believe that diversity drives innovation and strengthens our commitment to making positive changes for the patients we serve. As we observe #Juneteenth, we celebrate past victories, acknowledge present challenges, and commit to a better, more equitable future for all.
-
-
Come join us at Atavistik Bio! We are looking for a driven and strategic Associate Director, Business Development to contribute to our mission of discovering the next generation of precision allosteric therapeutics. Check out this great opportunity. https://lnkd.in/eYVpCUvT
-
We are proud to share that Maria-Jesus Blanco, SVP, Head of Chemical Sciences, is the 2024 recipient of The Division of Medicinal Chemistry Award. Congratulations on this outstanding achievement!
Announcing the 2024 recipient of The Division of Medicinal Chemistry Award, sponsored by the Thomas J. Perun Endowment Fund as Dr. Maria-Jesus Blanco from Atavistik Bio. Dr. Blanco has held leadership positions at Lilly, Sage Therapeutics and at Atavistik Bio. She has a strong track record for delivering development candidates, including 14 clinical candidates, 2 approved drugs, 1 in Phase 3, and 6 in Phase 2. Congratulations, Dr. Blanco! #MEDIAwards
-